Pseudoprogression versus true progression in patients with glioblastoma: A multiapproach analysis

Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review

(2022) Ingrid Sidibe et al.   Biomedicines

Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers

(2021) Clara Le Fèvre et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma

(2020) Paul Manning et al.   JOURNAL OF NEURO-ONCOLOGY

Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma

(2019) Arthur H. A. Sales et al.   JOURNAL OF NEURO-ONCOLOGY

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

(2019) Anne Laprie et al.   BMC CANCER

Pseudoprogression of brain tumors

(2018) Stefanie C. Thust et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

(2018) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients

(2018) Jung Youn Kim et al.   NEURO-ONCOLOGY

Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis

(2017) Bart R. J. van Dijken et al.   EUROPEAN RADIOLOGY

Response Assessment in Neuro-Oncology Clinical Trials

(2017) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?

(2016) Jonathan Khalifa et al.   JOURNAL OF NEURO-ONCOLOGY

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

(2016) Wolfgang Wick et al.   NEURO-ONCOLOGY

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

(2016) Nathalie L. Albert et al.   NEURO-ONCOLOGY

MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis

(2016) Praneil Patel et al.   NEURO-ONCOLOGY

Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging

(2016) Tomas Kazda et al.   NeuroImage-Clinical

The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis

(2015) Qun Wang et al.   EUROPEAN RADIOLOGY

Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis

(2015) Hui Zhang et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

(2015) Martin Bulik et al.   Biomed Research International

Evaluation of the Lactate-to-N-Acetyl-aspartate Ratio Defined With Magnetic Resonance Spectroscopic Imaging Before Radiation Therapy as a New Predictive Marker of the Site of Relapse in Patients With Glioblastoma Multiforme

(2014) Alexandra Deviers et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question

(2014) M. Nasseri et al.   NEURO-ONCOLOGY

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme

(2012) Gloria B. Roldán Urgoiti et al.   JOURNAL OF NEURO-ONCOLOGY

MR Spectroscopy Using Normalized and Non-normalized Metabolite Ratios for Differentiating Recurrent Brain Tumor from Radiation Injury

(2011) Augusto E. Elias et al.   ACADEMIC RADIOLOGY

Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and Temozolomide

(2011) Erkan Topkan et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Developing a Clinical Decision Model: MR Spectroscopy to Differentiate Between Recurrent Tumor and Radiation Change in Patients with New Contrast-Enhancing Lesions

(2009) Ethan A. Smith et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY